Forbion Growth Opportunities Fund III Cooperatief U.A.

CIK: 0002050895

Transaction Breakdown

Open Market Buys (P)2 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (50.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

BRVE

Braveheart Bio, Inc.

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (4 total)

BRVE
Braveheart Bio, Inc.
Aug 7, 2026
Conversion(C)
Direct
9.1M shares-
BRVE
Braveheart Bio, Inc.
Aug 7, 2026
Conversion(C)
Indirect
8M shares-
BRVE
Braveheart Bio, Inc.
Aug 7, 2026
Purchase(P)
Direct
1.9M shares at avg. $18.00$34.6M
BRVE
Braveheart Bio, Inc.
Aug 7, 2026
Purchase(P)
Indirect
1.7M shares at avg. $18.00$30.2M

		Type	Shares	Price		Ownership
Aug 7, 2026	BRVE Braveheart Bio, Inc.	Conversion(C)	9,132,420	-	$0	Direct
Aug 7, 2026	BRVE Braveheart Bio, Inc.	Conversion(C)	7,990,867	-	$0	Indirect
Aug 7, 2026	BRVE Braveheart Bio, Inc.	Purchase(P)	1,920,000	$18.00	$34,560,000	Direct
Aug 7, 2026	BRVE Braveheart Bio, Inc.	Purchase(P)	1,680,000	$18.00	$30,240,000	Indirect

1-4 of 4 transactions

About Forbion Growth Opportunities Fund III Cooperatief U.A.

Forbion Growth Opportunities Fund III Cooperatief U.A. (SEC CIK 0002050895) files insider reports with the SEC as 10% Owner of Braveheart Bio, Inc. (BRVE).

Signal8 holds 2 ownership filings by Forbion Growth Opportunities Fund III Cooperatief U.A. (1 Form 3, 1 Form 4), filed between Aug 5, 2026 and Aug 7, 2026. Those filings report 4 transactions, the latest on Aug 7, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Forbion Growth Opportunities Fund III Cooperatief U.A.'s filings is in NAARDEN.

Recent filings by Forbion Growth Opportunities Fund III Cooperatief U.A.

Aug 7, 2026: Conversions of BRVE shares (2 lines, Form 4, code C).
Aug 7, 2026: Open-market purchases of BRVE shares (2 lines, Form 4, code P).

Other insiders filing for Braveheart Bio, Inc. (BRVE)

Agarwala Vineeta, Director
AH Bio Fund IV, L.P., 10% Owner
Chimovits Erez, Director
ORBIMED ADVISORS LLC, Director
Jiangsu Hengrui Pharmaceuticals Co., Ltd., 10% Owner
Rickey James Paul, Chief Financial Officer

How to read Form 4 transaction codes